5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Supraventricular Tachycardia
Supraventricular Tachycardia (SVT) is a cardiac arrhythmia characterized by an abnormally fast heartbeat originating above the heart's ventricles. This condition is often caused by abnormal electrical pathways in the heart, leading to rapid and irregular heartbeats. SVT episodes can be brief or prolonged, causing symptoms such as palpitations, dizziness, and shortness of breath. While generally not life-threatening, SVT can significantly impact an individual's quality of life. Treatment options range from lifestyle modifications and medications to more invasive procedures like catheter ablation, aiming to restore a normal heart rhythm. Proper diagnosis and management of SVT are crucial to alleviate symptoms and prevent potential complications associated with this common heart rhythm disorder.
John R Doty
Intermountain Medical Center, United States
Trevor Tucker
Dynamic Vascular Resolution Inc., Canada
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Fatima Michelle Villa Jimenez
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico
Mancilla Sandoval Yoana Tenneth
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian FederationSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Surgical options for aortic valve preservation
John R Doty, Intermountain Medical Center, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina